📊 Дашборд — обзор экстракции BDNF
997
статей извлечено
0.13
средняя confidence
46
полей извлечено
4906
всего не-null значений
📋 Покрытие полей (по группам)
Идентификация (6 полей)
| Поле | Заполнено | % | Ср. confidence | Пример значения |
|---|---|---|---|---|
| Target | 387 |
38.8%
|
0.96 | |
| Alt. target | 315 |
31.6%
|
0.95 | |
| Protein family | 281 |
28.2%
|
0.88 | |
| Functional class | 245 |
24.6%
|
0.86 | |
| Subcellular loc. | 66 |
6.6%
|
0.84 | |
| Isoforms (metab/obesity) | 0 |
0.0%
|
0 |
Механизм действия (21 полей)
| Поле | Заполнено | % | Ср. confidence | Пример значения |
|---|---|---|---|---|
| Mechanism | 116 |
11.6%
|
0.93 | |
| Mutations (obesity/lean) | 24 |
2.4%
|
0.86 | |
| Activity (obesity) | 13 |
1.3%
|
0.82 | |
| Activity temporal | 3 |
0.3%
|
0.87 | |
| Energy balance | 22 |
2.2%
|
0.83 | |
| Appetite | 11 |
1.1%
|
0.87 | |
| Fat metabolism | 11 |
1.1%
|
0.84 | |
| Lipolysis | 1 |
0.1%
|
0.90 | |
| Thermogenesis | 5 |
0.5%
|
0.84 | |
| Muscle metabolism | 4 |
0.4%
|
0.91 | |
| Inflammation | 72 |
7.2%
|
0.88 | |
| Glucose metabolism | 16 |
1.6%
|
0.85 | |
| AA metabolism | 1 |
0.1%
|
0.80 | |
| Hormonal pathways | 32 |
3.2%
|
0.87 | |
| Cell death | 52 |
5.2%
|
0.87 | |
| Adipocyte fibrosis | 0 |
0.0%
|
0 | |
| Upstream (biochem) | 41 |
4.1%
|
0.86 | |
| Upstream (physiol) | 29 |
2.9%
|
0.87 | |
| Downstream (biochem) | 113 |
11.3%
|
0.89 | |
| Downstream (physiol) | 79 |
7.9%
|
0.88 | |
| PTMs | 18 |
1.8%
|
0.89 |
Экспрессия (8 полей)
| Поле | Заполнено | % | Ср. confidence | Пример значения |
|---|---|---|---|---|
| Tissue expression | 210 |
21.1%
|
0.91 | |
| In vitro | 178 |
17.9%
|
0.92 | |
| In vivo | 500 |
50.2%
|
0.93 | |
| In silico | 97 |
9.7%
|
0.91 | |
| Genetic association | 111 |
11.1%
|
0.90 | |
| Ex vivo | 58 |
5.8%
|
0.90 | |
| Animal model | 516 |
51.8%
|
0.93 | |
| Diet/model | 353 |
35.4%
|
0.92 |
Клиника (11 полей)
| Поле | Заполнено | % | Ср. confidence | Пример значения |
|---|---|---|---|---|
| Drug | 265 |
26.6%
|
0.97 | |
| Indication | 237 |
23.8%
|
0.92 | |
| Patient subgroups | 54 |
5.4%
|
0.85 | |
| Safety concerns | 27 |
2.7%
|
0.90 | |
| Off-target | 2 |
0.2%
|
0.80 | |
| Trial stage | 104 |
10.4%
|
0.88 | |
| Pharma competitors | 0 |
0.0%
|
0 | |
| AE severity | 1 |
0.1%
|
0.90 | |
| MOA weight loss | 8 |
0.8%
|
0.84 | |
| Endpoints | 55 |
5.5%
|
0.89 | |
| Approved | 173 |
17.4%
|
0.87 |
📈 Распределение confidence
462
0-0.1
327
0.1-0.2
121
0.2-0.3
52
0.3-0.4
12
0.4-0.5
23
0.5-0.6